期刊文献+

病原宏基因组高通量测序临床本地化检测规范专家共识 被引量:1

Expert consensus on clinical localization detection standards for metagenomic next generation sequencing of pathogens
原文传递
导出
摘要 感染性疾病严重危害人类生命健康,快速准确检测病原体是有效治疗和精准防控感染性疾病的关键环节。传统的病原学检验技术覆盖的微生物种类少,难以满足临床需求。宏基因组高通量测序(mNGS)理论上可同时检测所有已知基因序列的病原体,在很大程度上提高了临床疑难危重感染、罕见和新发病原体感染的诊断水平和救治能力。在个体化医疗需求的大背景下,新技术的实验室自建检测(LDT)能够持续提高临床诊治水平。由于mNGS技术平台研发起点高、操作流程复杂,为了保证该技术合理应用,保障患者医疗安全,本文在临床检验、感染、危重症及体外诊断等领域的专家就mNGS-LDT的流程搭建、性能确认、质量控制、报告审核等方面形成共识并提出规范要求和建议。 Infectious diseases seriously endanger human health.Rapid and accurate detection of pathogens is the key to effective treatment and precise prevention and control of infectious diseases.Traditional pathogen testing techniques cover a limited variety of microorganisms,making it difficult to meet clinical needs.Metagenomic Next Generation Sequencing(mNGS)theoretically can simultaneously detect all known gene sequences of pathogens,greatly improving the clinical capacity of diagnosing and treating patients with severe,complicated,rare,and emerging pathogen infections.In the context of individualized health needs,the laboratory developed test(LDT)of new technologies in laboratories can continuously improve the level of clinical diagnosis and treatment.Due to the high starting point of research and development and the complex operation process of the mNGS technology platform,this study reaches a consensus on the experimental procedure,assay validation,quality control,and report review of the mNGS-LDT in the fields of clinical testing,infection,critical care,and in vitro diagnosis to ensure the appropriate application of the technology and guarantee patient safety and proposes standardized requirements and suggestions.
作者 中国药师协会 中华医学会细菌感染与耐药防治分会 国家卫生健康委临床抗微生物药物敏感性折点研究和标准制定专家委员会 杨启文 王明贵 马筱玲 张建中 李轶 吴文娟 杨继勇 韩东升 李家斌 罗燕萍 周华 谷丽 张西京 李敏 单斌 胡付品 刘正印 周海健 Chinese Pharmacists Association;Branch of Bacterial Infection and Resistance Prevention of Chinese Medical Association;Expert Committee of the National Health Commission on Antimicrobial Susceptibility Testing and Standard Research;Yang Qiwen;Wang Minggui(不详;Department of Clinical Laboratory,Peking Union Medical College Hospital,Beijing 100730,China;Institute of Antibiotics,Huashan Hospital,Fudan University,Shanghai 200040,China)
出处 《中华预防医学杂志》 CAS CSCD 北大核心 2024年第4期454-465,共12页 Chinese Journal of Preventive Medicine
关键词 病原宏基因组测序 实验室自建检测 性能确认 质量控制 Metagenomic next generation sequencing Laboratory developed test Assay validation Quality control
  • 相关文献

参考文献18

二级参考文献144

  • 1何礼贤,潘珏,陈世耀,王爱霞,谢灿茂,申正义.替考拉宁治疗革兰阳性球菌感染的临床研究[J].中华内科杂志,2005,44(5):337-341. 被引量:29
  • 2<应用抗菌药物防治外科感染的指导意见>撰写协作组,王春生,陈昊.应用抗菌药物防治外科感染的指导意见(草案)ⅩⅧ——临床心脏移植感染的预防与治疗[J].中华外科杂志,2006,44(22):1563-1564. 被引量:3
  • 3马晓春,王辰,方强,刘大为,邱海波,秦英智,席修明,黎毅敏.急性肺损伤/急性呼吸窘迫综合征诊断和治疗指南(2006)[J].中国危重病急救医学,2006,18(12):706-710. 被引量:606
  • 4任南,文细毛,吴安华.全国医院感染横断面调查结果的变化趋势研究[J].中国感染控制杂志,2007,6(1):16-18. 被引量:352
  • 5无.肺真菌病诊断和治疗专家共识[J].中华结核和呼吸杂志,2007,30(11):821-834. 被引量:608
  • 6Flannery E, Danzis S. FDA plans to regulate laboratory developed tests as devices. Journal of Medical Device Regulation. [ EB/ OL ]. [ 2010-8 ] . http://www, coy. com/files/Publication/ 516 fd2e9-4edc-4 deO-8Odb-15 ba723 fb51 e/Presentation/ PublicationAttaehment/a5 d221 b6-600b-4be7-8cOa- 217tb00f3688/FDA% 20Plans% 20to% 20Regulate% 20Laboratory% 20Developed% 20Tests% 20as% 20Devices. pdf. 被引量:1
  • 7US Food and Drug Administration. Draft guidance for industry, food and drug administration staff, and clinical laboratories: framework for regulatory oversight of laboratory developed tests (LDT) . [ EB/OL ] . [ 2014-10-3 ] http ://www. fda. gov/ downloads/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/U CM416685. pdf. 被引量:1
  • 8Department of Health and Human Services, Food and DrugAdministration. Optimizing FDA's regulatory oversight of next generation sequencing diagnostic tests-preliminary discussion paper. [ EB/OL ] . [ 2014-12-9 ] . http://www, fda. gov/ downloads/medicaldevices/newsevents/workshops conferences/ ucm 427869. pdf. 被引量:1
  • 9Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health Optimizing FDA' s regulatory oversight of next-generation sequencing diagnostic tests. [ EB/OL]. [2015-2-20]. http:// www. fda. gov/downloads/MedicalDevices/NewsEvents! WorkshopsConferences/UCM439974. pdf. 被引量:1
  • 10Shuren J, Conway PK. FDA and CMS form task force on LDT quality requirements. [ EB/OL ] . [ 2015-4-16 ] . http:// blogs, fda. gov/fdavoice/index, php/2015/04/fda-and-cms-form- task -force -on -ldt-quality -requirements/. 被引量:1

共引文献1802

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部